

95 95 95 95

TARGETS UPDATE

July 22, 2024 ▪ Munich, Germany

Getting HIV Prevention on Track to Attain 2030 Targets The City of Paris

Jean-Michel Molina, MD

University of Paris Cité and Department of Infectious Diseases,
St-Louis and Lariboisière Hospitals, Paris, France

PrEP is Changing HIV Prevention



January 1st 2016

Oral PrEP with TDF/FTC Approved in France



“

J'ai décidé que le Truvada® serait pris en charge à partir de début 2016 dans le cadre d'une Recommandation Temporaire d'Utilisation qui sera publiée dans la première quinzaine de décembre.

(Marisol Touraine, Ministre de la Santé, Assemblée Nationale, nov. 2015)

Strong Community Involvement



City Hall Meeting, Paris, February 2016

**IL EXISTE PLUSIEURS MOYENS DE PRÉVENTION,
CHOISISSEZ CELUI QUI VOUS CONVIENT**

- 1**
PRÉSERVATIF :
« il y a toujours
un préservatif qui
vous va »
- 2**
LE DÉPISTAGE RÉPÉTÉ
(tests rapides autotests)
- 3**
LA PREP,
prophylaxie
pré-exposition,
désormais
remboursée
- 4**
EFFET PRÉVENTIF
du traitement pour
les personnes vivant
avec le VIH

LA MARNE
AU PONT DE CHAMPEL

Current PrEP Guidelines

- PrEP is a tool to prevent HIV infection in **adults and adolescents** exposed to HIV
- **Individualized approach** assessing past and future exposures to identify eligible persons
- People exposed to an **increased risk of HIV acquisition**:
 - MSM and transgender women or men
 - Heterosexuals men and women in a context of high HIV prevalence: high endemic countries, multiple partners, condomless sex, use of PEP, STIs...
 - IVDU sharing syringes
- Indications are not selection criteria but help guide the discussion with the patient to make a **shared decision** about PrEP initiation
- PrEP **not indicated** for a stable couple when HIV-positive partner has undetectable viral load

PrEP Delivery Integrated into Existing Services in France


- Hospital-based HIV clinics (01/2016)
- STI clinics (06/2016)
- GP renew prescriptions (2017) and initiate (6/21)
- PrEP delivered in hospital or private pharmacies



Roll-out of HIV PrEP with TDF/FTC in France (2016-2023)

- Using the French National Health Data System (SNDS) covering 99% of people in France from January 1st 2016 to June 30, 2023
- PrEP users defined as individuals ≥ 15 years, HIV negative, and who received at least one dispensing of TDF/FTC
- **97% are men** with a median age of 34 years (IQR:27-44)
- **41% live in the Ile de France region (23% in Paris)**, 10% in Auvergne-Rhone-Alpes and 9% in French Riviera, only 1,5% overseas departments
- **84,997 individuals have initiated PrEP since January 2016** (1559 initiations per month in 2022) and **52,800** are still using PrEP in 2023
- Up to **23% of new PrEP users have no prescription renewal** in following 6 months
- **Only 27% of PrEP initiations are prescribed by private practitioners and 31% of renewals**

PrEP in France Today



RESEARCH ARTICLE

Pre-exposure prophylaxis in France: How many MSM are eligible and how much will it cost?

Only 37% of MSM covered by PrEP (52,000/140,000)

Other key populations < 1%

PrEP is largely underutilized in France

Res

For 2

prev

145,

Men



roll-out in eligible MSM varied between € 317,685,216 and € 545,903,216 for official French criteria, which was higher than the estimated €432,240,851 and €742,753,074 according to the Menza score.

Real-World PrEP Effectiveness in Men at high risk of HIV-infection in France* (2016-2020)

	Cases	Controls	Adjusted OR (95% CI)	PrEP Effectiveness (95% CI)
PrEP non consumers	183 (71%)	622 (51%)	Ref	Ref
PrEP consumers				
All	73 (29%)	591 (49%)	0.40 (0.29-0.54)	60% (46, 71)
< 50% follow-up	57 (22%)	239 (20%)	0,82 (0.57-1.18)	18% (-18; 43)
50-74% follow-up	11 (4%)	117 (10%)	0.31 (0.16-0.59)	69% (41, 84)
> 75% follow-up	5 (2%)	235 (19%)	0.07 (0,03-0.16)	93% (84, 97)
Excluding Periods of PrEP Discontinuation	21 (10%)	417 (43%)	0.14 (0,08-0.22)	86% (78, 92)

*Men, 18-65 y, living in mainland France using PrEP or with ≥ 4 HIV tests with 1 STI: Using the SNDS 46706 individuals: 256 cases with HIV and 5 matched controls per case (age, socioeconomic status, place of residence, calendar year, follow-up)


New HIV Diagnoses in France by Region (2022)



Number of residents (2024)
 France: 68 M
 Ile de France: 12 M
 Paris: 2 M

New HIV Diagnoses in France (2012- 2022)


Decline by 11% 2012-22 (~5,700 cases) and by 32% among MSM born in France (56% in Paris)



Recent HIV Infections and Missed Opportunities for PrEP in France

- Multicenter study in people diagnosed with recent HIV-infection (4/2019 - 11/2020)
- **163 MSM + 2 TGW (89%)**, 10 men (5%), 2 IVDU and 8 women (4%)
- Median age of 33 years, and 71% born in metropolitan France
- **91% were eligible for PrEP but only 11% used PrEP (3.8% at diagnosis)**
- 140 (75.7%) have heard about PrEP but 120 did not use PrEP :
 - HIV infection diagnosed at PrEP initiation (33%)
 - Fear of side effects (33%)
 - Low perceived risk of HIV-infection (28%)
 - Not being offered (24%)
 - Not knowing where to get it (20%)
 - Fear of stigma (8%)

PrEP Use by HIV Negative MSM at Last Anal Sexual Intercourse with a Casual Partner in France




The Elephant in the Room


Addressing
Uncomfortable
Truths



Condom Use by HIV Negative MSM at Last Anal Sexual Intercourse with a Casual Partner in France



Preventive Tools used by HIV Negative MSM at Last Anal Sexual Intercourse with a Casual Partner (Paris)



Factors associated with no-PrEP use among MSM eligible for PrEP

	N (%)	Adjusted OR	95% CI	P-value
Age < 25 y	636 (76%)	3.19	2,47-4,13	<0.001
Age > 45 y (ref)	981 (46%)			
Low education	1056 (65%)	1.75	1.44-2.13	<0.001
University degree (ref)	1075 (37%)			
Live in small city	606 (65%)	1.37	1.08-1.74	0.009
Live in large city (ref)	1049 (37%)			
Low income	451 (60%)	1.39	1.10-1.77	0.007
High income (ref)	1814 (45%)			
GP and discuss sex				
No	1883 (82%)	3.13	2.65-3.69	<0.001
Yes (ref)	1278 (31%)			

*MSM eligible to PrEP: with no systematic use of condoms during anal intercourse in the last 6 months: 49.1% did not use PrEP

Summary

- High incidence of HIV in key populations in France.
- PrEP: highly effective biomedical tool and multiple options will be soon available.
- PrEP and Condoms should be used in combination.
- Awareness campaigns for condoms and biomedical prevention of HIV are clearly insufficient and should be targeted to those most in need.
- The goal is to **increase the use of combination prevention from 80% to 95% in those exposed to HIV**
- All stakeholders need to be involved, especially the community.



20th EUROPEAN AIDS CONFERENCE

15–18 October 2025
Paris, France

#EACS2025



EACS European
AIDS Clinical Society

www.eacs-conference2025.com



@jmmolinaparis

Acknowledgments



BILL & MELINDA
GATES foundation

